Get the Stockscreener App
1.11
5.13%
-0.06
After Hours:
1.12
0.01
+0.90%
Immunic Inc stock is traded at $1.11, with a volume of 4.28M.
It is down -5.13% in the last 24 hours and up +88.46% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.17
Open:
$1.19
24h Volume:
4.28M
Relative Volume:
1.43
Market Cap:
$133.52M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.5261
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+17.13%
1M Performance:
+88.46%
6M Performance:
+45.86%
1Y Performance:
-5.13%
1-Day Range:
$1.11
$1.2799
1-Week Range:
$0.943
$1.2799
52-Week Range:
$0.5062
$1.35
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.11 | 140.73M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions - Dentons
IMUX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunic to present at healthcare investor conferences in March - Yahoo Finance
Immunic to Participate in Investor Conferences in March - ChartMill
Head to Head Review: Neuphoria Therapeutics and Immunic - National Today
Reverse stock split vote at Immunic (NASDAQ: IMUX) tied to Nasdaq listing - Stock Titan
Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight - Barchart.com
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
H.C. Wainwright cuts Immunic stock price target on share count changes - Investing.com
HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price - MarketBeat
Aug Opening: Can Immunic Inc sustain earnings growthMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Immunic secures $400M to support late-stage MS trialsICYMI - Proactive financial news
Trails Edge Capital Partners, LP Acquires Significant Stake in Immunic Inc - GuruFocus
BVF group details large Immunic (IMUX) pre-funded and common warrants - Stock Titan
IMMUNIC (IMUX) director Robert Nagel files initial insider Form 3 - Stock Titan
Immunic CEO on $400m financing, phase 3 MS plans - Proactive financial news
Immunic sets stage for phase 3 MS data readout after $400M financing - Yahoo Finance
Immunic: Fourth Quarter Financial Overview - Bitget
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic: Q4 Earnings Snapshot - Barchart.com
Immunic (NASDAQ: IMUX) details 2025 loss and $200M private placement - Stock Titan
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Commodore holds 13.35M IMUX shares, mostly warrant-based (IMUX) - Stock Titan
Trails Edge reports 11.45M-share position in Immunic (IMUX) via warrants - Stock Titan
Why did IMUX stock surge 33% pre-market today? - MSN
IMUX Stock Price, Forecast & Analysis | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
What’s the beta of Immunic Inc. stock2025 Earnings Impact & Long-Term Investment Growth Plans - mfd.ru
Why Immunic Inc. stock is seen as undervaluedJuly 2025 Macro Moves & Safe Entry Trade Reports - mfd.ru
Vivo Opportunity files for Immunic (IMUX): 9.99% stakes via exercisable warrants - Stock Titan
What Does the Market Think About Immunic Inc? - Benzinga
Immunic Therapeutics - The Pharma Letter
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Immunic rises after $400M private placement, leadership transition - MSN
Immunic closes $200 million financing, may receive additional $200m By Investing.com - Investing.com Australia
Funding to support Immunic Phase 3 MS trials, commercialization - Multiple Sclerosis News Today
Immunic closes $200 million private placement - The Pharma Letter
Immunic closes $200 million financing, may receive additional $200m - Investing.com
Immunic closes $200M private placement to fund late-stage MS trials - Yahoo! Finance Canada
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic Announces Closing of Oversubscribed Private Placement Financing - PR Newswire
How Immunic Inc. stock reacts to global recession fearsJuly 2025 WrapUp & Reliable Intraday Trade Plans - mfd.ru
VIX Spike: Is Immunic Inc stock a good dividend stockWeekly Gains Report & Safe Entry Zone Identification - baoquankhu1.vn
Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors - marketscreener.com
Immunic (IMUX) Is Up 27.8% After Securing Oversubscribed $400M Raise For MS Push – What's Changed - simplywall.st
A Look At Immunic (IMUX) Valuation After Oversubscribed Funding And Leadership Changes - Yahoo Finance
Biogen Appoints Dr. Gabriela Freire as Board Chair While Immunic Inc. Searches for New CEO - geneonline.com
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):